Kibalian v Allergan Inc., 2022 ONSC 1827
Consortium including RHE Lawyers obtain certification of issues relating to Anaplastic Large Cell Lymphoma and Allergan breast implants
On March 23, 2022, Justice Morgan of the Ontario Superior Court of Justice granted certification of common issues relating to the propensity of Allergan Biocell® implants to cause Anaplastic Large Cell Lymphoma (“ALCL”). This means that the issues relating to ALCL are authorized to proceed to a common issues trial. The reasons for judgment of Justice Morgan and the entered order for certification can be found here.
The Plaintiffs also intend to seek certification of additional issues relating to all silicone breast implants manufactured and sold in Canada by Allergan since 1999, due to their propensity to cause autoimmune disease (sometimes termed “ASIA” or “BII”) and premature rupture. The certification hearing of those issues will proceed in the Ontario Superior Court of Justice on September 28-30, 2022.
If you have developed ALCL due to your Allergan breast implants, we encourage you to contact Ying Lee, Senior Paralegal, at ylee@rhelaw.com . We will provide updates on our website as the matter progresses and will also be offering a town hall Q&A meeting for class members in advance of the continuation of the certification hearing in September to provide further information.